Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aumolertinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Lung Neoplasms 7 Brain Neoplasms 2 Radiation Pneumonitis 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 NSCLC 1 Meningeal Carcinomatosis 1 Carcinoma 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Carboplatin 20 Cisplatin 15 Pemetrexed 14 pembrolizumab 13 Paclitaxel 13 Gemcitabine 8 osimertinib 6 durvalumab 6 Docetaxel 6 Nivolumab 5 Erlotinib Hydrochloride 4 130-nm albumin-bound paclitaxel 4 brigatinib 3 Gefitinib 3 vosaroxin 2 volociximab 2 pralsetinib 2 ensartinib 2 atezolizumab 2 anlotinib 2 aflibercept 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Ipilimumab 2 Drug Therapy 2 Cyclophosphamide 2 Cetuximab 2 Albumin-Bound Paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡